Current pharmacologic therapies to prevent occurrence of skin cancers include retinoid therapy, nicotinamide and the modulation of immunosuppression by converting from calcineurin inhibitors to mammalian target of rapamycin (mTOR) pathway inhibitors [5, 7–9]. This evidence concerns the gene MTOR and skin cancer.